Pluto Immunotherapeutics

Pluto Immunotherapeutics is a biotechnology company dedicated to developing the next generation of "off-the-shelf" cellular immunotherapies for the treatment of autoimmune diseases and cancer. Co-founded by prominent researchers from UCLA and Memorial Sloan Kettering Cancer Center, the company leverages a proprietary Artificial Thymic Organoid (ATO) platform to differentiate pluripotent stem cells (iPSCs) into mature, functionally enhanced T cells. Its current research pipeline includes an autologous CAR T cell therapy targeting progressive multiple sclerosis and a scalable allogeneic platform for generating tumor-optimized T cells. By utilizing a renewable cell source and advanced gene editing, Pluto Immunotherapeutics aims to overcome the cost, scalability, and efficacy limitations associated with traditional patient-derived cell therapies.